No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
103 |
4. Check minimum number of eventsNone |
103 |
5. Include endpointsNone |
103 |
6. Filter based on genotype QC (FinnGen only) |
100 |
Control definitions (FinnGen only)
- Control exclude
- G6_DEMYEL
Extra metadata
- Level in the ICD hierarchy
- 4
Similar endpoints
↥List of similar endpoints to
Neuromyelitis optica
based on the number of shared cases.
Similar with more cases:
- Other acute disseminated demyelination
- Demyelinating diseases of the central nervous system
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
- Neurological diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 100 | 81 | 19 |
| Unadjusted period prevalence (%) | 0.02 | 0.03 | 0.01 |
| Median age at first event (years) | 43.03 | 41.82 | 48.18 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 103
- Matched controls
- 1030
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
133.3
97
*
G35
ICD-10 Finland
Multiple sclerosis
+∞
74.2
62
*
H46
ICD-10 Finland
Optic neuritis
395.5
69.8
63
*
109
Kela drug reimbursment
Multiple sclerosis
+∞
54.0
47
*
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
+∞
50.2
44
*
XCK00
NOMESCO Finland
Perimetry
26.7
49.7
39
23
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
+∞
45.2
40
*
L03AB07
ATC
interferon beta-1a; parenteral
+∞
35.5
32
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
12.3
35.1
47
66
L03AX13
ATC
glatiramer acetate; parenteral
+∞
33.1
30
*
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
+∞
29.6
27
*
TAB00
NOMESCO Finland
Lumbar puncture
13.0
29.0
33
36
ZX120
NOMESCO Finland
Intravenous
11.0
27.9
37
50
N86
ICPC
Multiple sclerosis
+∞
26.2
24
*
XA800
NOMESCO Finland
Neuropsychological investigation
11.7
22.2
26
29
Z01.0
ICD-10 Finland
Examination of eyes and vision
7.0
21.3
47
110
164
Kela drug reimbursment
Fingolimod
+∞
19.4
18
*
L04AA27
ATC
[U] fingolimod
+∞
18.3
17
*
353
Kela drug reimbursment
Cladribine and fingolimod
+∞
17.1
16
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
7.5
16.4
28
49
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
7.0
14.9
27
50
XCD10
NOMESCO Finland
Electrophysiological examination of eye
27.1
14.9
20
9
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
35.8
14.4
18
6
L03AB08
ATC
interferon beta-1b; parenteral
+∞
13.9
13
*
L04AA31
ATC
[U] teriflunomide
+∞
12.8
12
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
26.7
12.0
16
7
G04BD12
ATC
mirabegron; oral
6.3
11.9
23
45
N04BB01
ATC
amantadine; oral
73.5
11.9
13
*
2AB04, ,
NOMESCO Finland
+∞
11.7
11
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
6.2
11.6
23
46
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
14.3
11.4
19
16
L04AX01
ATC
azathioprine; systemic
13.4
11.1
19
17
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.1
10.8
27
67
Z3226
NOMESCO Finland
Physiotherapist
4.4
10.7
36
113
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
15.4
10.6
17
13
M03BX01
ATC
baclofen; systemic
22.8
10.1
14
7
L28
ICPC
Limited function/disability (L)
4.3
9.8
32
98
N99
ICPC
Neurological disease other
109.7
9.6
10
*
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
+∞
9.5
9
*
N07XX09
ATC
[U] dimethyl fumarate
+∞
9.5
9
*
R1250
NOMESCO Finland
Evaluation of functional capability
12.4
9.2
16
15
UKC02
NOMESCO Finland
Cystoscopy
4.9
9.1
23
57
XKD06
NOMESCO Finland
Physiologic investigation of micturition
16.0
9.0
14
10
H53.1
ICD-10 Finland
Subjective visual disturbances
5.3
8.8
20
45
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
30.4
8.7
11
*
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
+∞
8.4
8
*
R20.2
ICD-10 Finland
Paraesthesia of skin
4.6
8.2
22
57
XKC03
NOMESCO Finland
Water cystometry
14.7
8.1
13
10
G04BD09
ATC
trospium; oral
27.4
7.7
10
*
XCK10
NOMESCO Finland
Photography of fundus of eye
5.0
7.6
18
42
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
17.4
7.4
11
7
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
+∞
7.4
7
*
WW400
NOMESCO Finland
Plasmaferesis
+∞
7.4
7
*
N06BA07
ATC
modafinil; oral
+∞
7.4
7
*
L04AE01
ATC
fingolimod; oral
+∞
7.4
7
*
N39.4
ICD-10 Finland
Other specified urinary incontinence
4.9
7.4
18
43
ZXA10
NOMESCO Finland
Bilateral
3.5
7.0
29
103
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
18.2
6.9
10
6
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
24.4
6.8
9
*
J01EA01
ATC
trimethoprim; systemic
3.0
6.8
43
197
A28
ICPC
Limited function/disability NOS
4.1
6.7
21
61
Z3231
NOMESCO Finland
Registered nurse
3.0
6.7
42
191
R5110, ,
SPAT
5.8
6.6
18
36
A02BC02
ATC
pantoprazole; systemic
3.6
6.5
84
566
G04BD08
ATC
solifenacin; oral
7.1
6.4
15
24
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
+∞
6.3
6
*
L04AK02
ATC
teriflunomide; oral
+∞
6.3
6
*
L04AX07
ATC
dimethyl fumarate; oral
+∞
6.3
6
*
TimeCodeWAS
↥TimeCodeWAS is a tool for exploring time-dependent associations between an endpoint and health codes (diagnoses, lab tests, procedures, etc.).
The TimeCodeWAS analysis is done in three steps:
- Build a matched case-control set for this endpoint. Each case is matched to 5–10 controls on sex and year of birth, and controls must be at risk at the same age as the case's age of onset. TimeCodeWAS allows for controls to be reused.
- Count cases and controls. For each health code, and for each time window: tally the counts into a 2×2 table. To be eligible in a time window, a case or control must have data coverage for at least 50% of that time window.
- Perform association tests. If all cells of the 2×2 table have N≥10, then a χ² test is performed, otherwise a Fisher's exact test is done. The corresponding p-value and confidence interval are reported below, along with the standard odds ratio when a χ² test is done, or Fisher's MLE odds ratio otherwise.
TimeCodeWAS currently uses the same default set of time windows for all the endpoints. Please reach out to us if you have suggestions for better time windows for some endpoints.
The default time windows are:
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
25
13
24.89
17.96
1.3
1.2
—
—
—
0
0
48
171
4.38
12.29
4.9
2.5
5.74
12.57
e6/l
0.78
40
153
61
271
4.07
11.23
8.6
2.9
—
—
—
0
0
52
224
3.67
9.69
8.1
2.7
0.12
0.27
e6/l
0.73
44
153
13
6
24.50
9.62
8.4
3.3
—
—
—
0
0
13
6
24.50
9.62
1.1
1.0
—
—
—
0
0
84
525
4.25
8.26
23.4
10.3
3.67
3.95
e9/l
0.65
79
458
75
459
3.33
7.11
7.3
3.1
0.00
0.00
estimate
-0.00
24
97
75
465
3.25
6.84
7.2
3.2
0.00
0.00
estimate
-0.00
23
97
75
473
3.15
6.48
7.3
3.3
0.00
0.00
estimate
-0.00
23
87
31
123
3.17
6.19
7.8
2.6
4.53
2.50
e6/l
0.48
19
53
10
10
10.92
5.67
1.0
1.5
—
—
—
0
0
10
12
9.08
5.19
1.0
1.3
—
—
—
0
0
10
12
9.08
5.19
1.0
1.3
—
—
—
0
0
66
419
2.60
5.11
4.0
2.4
95.99
71.97
nmol/l
6.87
60
387
31
140
2.74
4.80
7.9
2.5
1.05
0.99
e6/l
0.05
19
69
46
253
2.48
4.76
8.0
3.3
0.00
0.00
estimate
-0.00
24
92
9
11
8.83
4.66
1.0
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
7
5
14.87
4.64
1.0
1.4
—
—
—
0
0
8
8
10.71
4.60
1.0
1.5
2.06
2.20
mmol/l
—
8
8
13
30
4.80
4.30
1.8
2.1
—
—
—
0
0
12
31
4.24
3.63
1.6
1.4
—
—
—
0
0
6
6
10.51
3.54
1.0
1.0
—
—
—
0
0
53
342
2.13
3.49
7.4
3.0
0.00
0.00
estimate
-0.00
20
78
42
257
2.07
3.10
5.7
2.6
0.00
0.01
estimate
0.49
21
75
9
21
4.59
3.07
1.7
1.6
—
—
—
0
0
5
5
10.41
3.01
1.0
1.8
—
—
—
0
0
6
9
6.99
2.91
1.0
1.0
—
—
—
0
0
9
27
3.55
2.46
6.7
3.7
2.80
3.33
g/l
—
9
27
33
211
1.83
2.02
2.2
1.9
0.68
1.22
mg/l
0.95
22
168
13
58
2.42
2.00
2.2
1.3
—
—
—
0
0
31
197
1.82
1.93
6.6
3.3
1.02
1.02
kg/l
0.48
23
119
7
23
3.19
1.83
2.3
1.5
—
—
—
0
0
17
89
2.09
1.83
7.7
2.9
34.35
29.64
u/l
0.35
17
75
10
41
2.59
1.70
1.3
1.3
—
—
—
0
0
53
409
1.61
1.56
10.7
6.4
1.22
1.22
mmol/l
0.22
47
362
5
15
3.45
1.54
3.4
3.5
—
—
—
0
0
18
103
1.91
1.53
13.8
7.3
104.00
104.41
mmol/l
0.12
18
103
21
127
1.82
1.51
2.0
1.6
—
—
—
0
0
7
29
2.51
1.42
1.7
1.2
—
—
—
0
0
37
268
1.59
1.39
2.7
2.4
52.38
69.71
u/l
0.55
37
251
11
54
2.16
1.38
1.5
1.3
—
—
—
0
0
36
260
1.59
1.36
1.4
1.3
0.80
1.57
u/ml
—
10
79
8
36
2.32
1.27
2.1
1.5
—
—
—
0
0
5
19
2.71
1.23
3.8
1.1
—
—
—
0
0
16
95
1.81
1.22
2.3
1.9
264.87
373.36
nmol/l
1.49
16
89
23
153
1.65
1.20
3.0
2.6
2.46
2.45
mmol/l
0.12
23
136
7
30
2.43
1.15
1.7
1.2
—
—
—
0
0
7
32
2.27
1.10
3.6
3.4
206.86
166.56
%
—
7
32
22
148
1.62
1.10
4.2
3.4
16.00
459.52
ng/l
1.12
13
98
9
47
2.00
1.05
1.6
1.7
—
—
—
0
0
7
35
2.07
1.02
3.1
2.9
101.29
101.80
%
—
7
35
15
93
1.72
1.00
2.0
1.4
—
—
—
0
0
0
30
0.00
0.99
0.0
1.2
—
1.27
—
0
20
11
62
1.87
0.98
2.7
3.0
—
—
—
0
0
11
62
1.87
0.98
4.7
8.9
119.27
122.39
g/l
0.20
11
62
39
305
1.45
0.98
2.7
3.3
46.17
27.31
ng/l
0.28
25
171
7
37
1.96
0.96
27.0
4.2
25.06
24.72
mmol/l
—
7
37
14
87
1.71
0.93
4.9
1.8
—
—
—
0
0
14
88
1.68
0.90
1.9
1.5
—
—
—
0
0
8
43
1.93
0.90
11.4
2.3
1.86
1.37
%
—
8
43
23
165
1.51
0.88
1.9
1.9
—
—
—
0
0
76
681
1.44
0.85
3.5
3.7
—
—
—
0
0
21
152
1.48
0.77
1.9
1.8
—
—
—
0
0
11
68
1.69
0.75
5.1
1.8
—
—
—
0
0
9
56
1.66
0.75
1.0
1.1
—
—
—
0
0
5
25
2.05
0.73
1.0
1.1
—
—
—
0
0
5
25
2.05
0.73
2.4
2.0
—
—
—
0
0
92
864
1.61
0.72
27.3
12.0
94.59
87.50
ml/min/173m2
4.04
85
808
94
894
1.59
0.66
28.8
13.6
139.70
139.94
mmol/l
0.48
94
880
50
430
1.32
0.66
3.9
2.6
—
—
estimate
—
0
0
80
854
0.72
0.64
4.3
3.9
1.28
1.25
mmol/l
0.18
73
801
27
214
1.35
0.61
4.3
2.0
—
—
—
0
0
0
20
0.00
0.61
0.0
1.3
—
—
—
0
0
5
89
0.54
0.59
1.6
1.5
—
—
—
0
0
95
905
1.64
0.59
29.3
13.1
15.19
20.09
mg/l
0.93
83
730
6
38
1.61
0.55
7.2
7.2
15.67
16.12
%
—
6
38
6
38
1.61
0.55
3.7
2.0
0.19
0.23
g/l
—
6
38
80
751
1.29
0.45
5.9
4.7
14.71
14.52
pmol/l
0.32
74
711
5
31
1.64
0.43
1.6
1.8
—
—
—
0
0
5
32
1.59
0.43
1.2
1.3
—
—
—
0
0
7
103
0.66
0.42
4.7
4.6
31.43
34.20
%
—
7
69
5
33
1.54
0.42
1.2
1.2
—
56.50
—
0
5
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
84
878
0.77
0.40
4.4
4.4
5.67
5.74
mmol/l
0.24
79
826
25
208
1.27
0.40
1.3
1.3
3.92
6.15
u/ml
—
9
82
0
19
0.00
0.39
0.0
1.3
—
—
—
0
0
98
951
1.63
0.37
33.9
15.8
64.90
70.26
umol/l
2.73
98
939
6
41
1.49
0.37
1.0
1.3
—
2.65
—
0
8
86
893
0.78
0.35
4.6
4.7
1.52
1.52
mmol/l
0.04
80
849
6
87
0.67
0.34
7.0
4.1
6.83
5.36
ug/l
—
6
67
91
877
1.32
0.33
7.1
5.5
1.71
1.77
mu/l
0.22
86
826
88
907
0.80
0.27
5.0
5.2
2.82
2.83
mmol/l
0.05
82
866
24
209
1.19
0.26
2.3
3.6
149.67
777.94
ng/l
4.74
19
173
5
37
1.37
0.24
2.4
4.5
3.34
0.55
mmol/l
—
5
30
7
92
0.74
0.23
19.1
6.4
—
—
—
0
0
25
221
1.17
0.23
1.3
1.3
14.08
17.79
iu/ml
—
6
73
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
9
112
0.78
0.21
1.6
1.7
1.47
1.29
%
—
9
102
0
13
0.00
0.21
0.0
2.9
—
156.39
—
0
7
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
7.64
—
0
14
39
362
1.12
0.18
3.0
2.0
98.68
97.74
pmol/l
0.03
24
190
7
60
1.18
0.18
1.4
1.4
—
—
—
0
0
27
247
1.13
0.15
1.9
1.6
—
—
—
0
0
5
43
1.17
0.10
1.2
1.1
0.80
0.98
g/l
—
5
43
5
45
1.12
0.10
2.0
1.2
—
—
—
0
0
12
107
1.14
0.09
3.3
4.7
1.04
1.58
ug/l
0.67
12
87
40
411
0.96
0.04
2.1
1.8
1.30
1.38
mmol/l
0.24
34
359
27
265
1.03
0.00
1.6
1.6
—
—
—
0
0
5
49
1.02
0.00
9.2
7.1
24.80
25.66
mmol/l
—
5
49
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
276.80
—
0
5
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
12.66
—
0
7
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
13.76
—
0
5
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: G6_NMO – Neuromyelitis optica
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).